# Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy

- Link: https://www.thailand-business-news.com/pr-news/leads-biolabs-opamtistomig-pd-l1-4-1bb-bispecific-antibody-nda-accepted-by-nmpa-poised-to-become-worlds-first-approved-4-1bb-targeting-therapy
- Published: 2026-08-21T16:20:00+07:00
- Author: PR Newswire

NANJING, China, Aug. 21, 2026 /PRNewswire/ — Nanjing Leads Biolabs Co., Ltd. ("Leads
Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug
Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has 
accepted the New Drug Application (NDA) for Opamtistomig (LBL-024), the Company’s
proprietary PD-L1/4-1BB bispecific antibody, as a monotherapy for the treatment 
of previously treated advanced extrapulmonary neuroendocrine carcinoma (EP-NEC).

Opamtistomig is the first PD-L1/4-1BB bispecific antibody globally to enter NDA 
review and was granted Priority Review by the CDE on July 10, 2026. If approved,
Opamtistomig would become the world’s first approved antibody drug directly targeting
4-1BB, as well as the first approved agonistic antibody. This milestone would also
make 4-1BB the fourth immuno-oncology target worldwide with an approved therapy,
following PD-1/PD-L1, CTLA-4 and LAG-3.

The NDA is supported by positive results from a registrational clinical study led
by Professor Shen Lin of Peking University Cancer Hospital and conducted across 
34 clinical sites. The study completed enrollment of 96 patients with EP-NEC in 
August 2025. Detailed results are planned for presentation at a leading international
medical congress.

**Executive Commentary**

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, said: "The acceptance of
Opamtistomig’s NDA marks a major milestone in our mission to develop differentiated
immunotherapies for patients with high unmet medical needs. Opamtistomig has received
multiple regulatory designations that have accelerated its development, including
Breakthrough Therapy Designation and Priority Review from China’s CDE, Orphan Drug
Designation and Fast Track designation from the U.S. FDA, and Orphan Drug Designation
from the European Medicines Agency.

As the first 4-1BB-targeting bispecific antibody globally to advance into registrational
clinical development, Opamtistomig represents a significant breakthrough in the 
treatment of EP-NEC, a highly aggressive, immunologically ‘cold’ tumor for which
there are currently no approved therapies worldwide. Beyond EP-NEC, we are advancing
our clinical program across multiple high-burden indications, including non‑small
cell lung cancer, biliary tract cancer, hepatocellular carcinoma, esophageal squamous
cell carcinoma, and ovarian cancer. Clinical data generated from seven indications
have shown promising antitumor activities and support the broad therapeutic potential
of Opamtistomig.

We believe Opamtistomig has the potential to become a cornerstone of next-generation
immunotherapy and to establish a new paradigm for T-cell agonist development. The
NDA acceptance represents an important validation of our differentiated approach
and brings us one step closer to delivering a novel treatment option to patients
with limited therapeutic alternatives."

Dr. Xiaoqiang Kang, Founder, Chairman, and CEO of Leads Biolabs, added: "The acceptance
of Opamtistomig’s NDA marks a critical step forward as Leads Biolabs transitions
toward commercialization. Since our founding, we have deliberately moved beyond 
the highly competitive PD-1/PD-L1 space to pursue differentiated mechanisms and 
address areas of significant unmet medical needs, with 4-1BB representing one of
the most promising frontiers in immuno-oncology.

Today, Opamtistomig stands poised to become the world’s first approved 4-1BB-targeting
drug. This achievement reflects our 14-year commitment to differentiated innovation
and our determination to tackle some of the most challenging targets in oncology.

We are grateful to the patients, investigators, clinical research teams, regulatory
authorities, and all our employees and partners who have contributed to the development
of Opamtistomig. We will work closely with regulatory authorities throughout the
review process to bring Opamtistomig to patients as quickly as possible."

**About EP-NEC**

Neuroendocrine carcinoma ("NEC") is a highly malignant immunologically "cold" tumor,
accounting for approximately 10% to 20% of neuroendocrine neoplasms. NEC may arise
in various organs, including the lung, gastrointestinal tract and bladder. NEC can
be classified into pulmonary NEC and extrapulmonary NEC. EP-NEC shares the highly
aggressive and metastatic characteristics of small cell lung cancer ("SCLC"), progresses
rapidly, and most patients with NEC present with advanced-stage disease or distant
metastases at diagnosis. Systemic treatment options for NEC are limited, with suboptimal
efficacy and poor prognosis.

There are currently no therapies specifically approved by regulatory authorities
worldwide for EP-NEC. First-line treatment for advanced EP-NEC primarily consists
of platinum-based chemotherapy, with an objective response rate ("ORR") of approximately
30% to 50% and a median overall survival ("mOS") of only around one year. There 
is no standard treatment following progression on first-line therapy. Second-line
treatment options may include oxaliplatin-based FOLFOX, irinotecan-based FOLFIRI,
CAPTEM with or without bevacizumab, or temozolomide monotherapy. However, the efficacy
of these treatment options remains limited, with an ORR of approximately 10% to 
25% and an mOS of approximately eight months. Accordingly, there remains a substantial
unmet medical need for patients with advanced EP-NEC, underscoring the urgent need
for new and effective treatment options.

**About Opamtistomig**

Opamtistomig (LBL-024) is emerging as a next-generation pan-cancer backbone therapy
with potential overall survival (OS) benefit that simultaneously targets PD-L1 and
the co-stimulatory receptor 4-1BB. Developed using Leads Biolabs’ proprietary X-
Body bispecific platform, Opamtistomig is designed to simultaneously block PD-1/
L1 immune suppression and conditionally activate 4-1BB, an agonist pathway, resulting
in a potent and synergistic anti-tumor immune response. It has a safety profile 
comparable to PD-1/PD-L1 inhibitors and demonstrates broader-spectrum anti-cancer
potential. To date, Opamtistomig has demonstrated first- or best-in-class potential
in Phase II or registrational clinical trials across multiple indications, including
non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract
cancer (BTC), and extrapulmonary neuroendocrine carcinoma (EP-NEC).

As the first 4-1BB-targeting bispecific antibody globally to advance to a single-
arm pivotal trial as monotherapy, Opamtistomig has been evaluated in 13 solid tumor
indications in China, including 1 pivotal registration trial and 8 proof-of-concept
studies. These cover EP-NEC, NSCLC, SCLC, BTC, ovarian cancer (OC), esophageal squamous
cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-
negative breast cancer (TNBC), malignant melanoma, and other areas with high unmet
medical needs.

Mechanistically, 4-1BB agonism can reactivate exhausted T cells and promote robust
T-cell proliferation, offering significant promise for PD-1/PD-L1–resistant or immunologically"
cold" tumors, and has the potential to deliver durable, long-tail survival benefits.
Recognizing its clinical potential, Opamtistomig received Breakthrough Therapy Designation(
BTD) from China’s National Medical Products Administration (NMPA) in October 2024,
and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA)
for the treatment of neuroendocrine carcinoma in November 2024. Additionally, in
January 2026, Opamtistomig was granted Fast Track Designation (FTD) by the FDA and
ODD by the European Commission for the treatment of EP-NEC, further underscoring
its potential to address unmet medical needs in this patient population.

**About Leads Biolabs**

Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated
to the discovery, development, and commercialization of innovative therapies to 
address underserved medical needs in oncology, autoimmune, and other severe diseases
both in China and globally.

Leads Biolabs is a front-runner in next-generation immuno-oncology treatments with
a differentiated pipeline of 14 innovative drug candidates, including five clinical-
stage drug candidates and one registration-stage asset.

The Company adopts a science-driven R&D approach and has successfully established
comprehensive R&D capabilities spanning antibody discovery and engineering, in vivo
and in vitro efficacy evaluation, as well as druggability assessment. It has also
developed multiple proprietary technology platforms, including LeadsBody (a CD3 
T-cell engager platform), X-body (a 4-1BB engager platform), TOPiKinectics (an ADC
platform) and ImBiTDC (a TDC platform), which serve as the cornerstone for its continued
innovation and have been validated by the clinical outcomes of its bispecific antibody
portfolios.

Leads Biolabs has established integrated capabilities across early discovery, translational
medicine, clinical development, CMC and business development. The innovative nature
and competitive strengths of its drug candidates, coupled with its global perspectives,
proactive strategy, and efficient clinical validation, have made it an attractive
partner for leading industry players and investment institutions. For more information,
please visit [https://en.leadsbiolabs.com/](https://en.leadsbiolabs.com/)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy ](http://www.prnasia.com/story/archive/5031249_CN31249_0?rand=184833)
